William Blair Issues Optimistic Outlook for Insulet Earnings

Insulet Co. (NASDAQ:PODD - Free Report) - Investment analysts at William Blair boosted their Q4 2024 EPS estimates for Insulet in a report issued on Monday, November 11th. William Blair analyst M. Andrew now anticipates that the medical instruments supplier will earn $1.18 per share for the quarter, up from their previous estimate of $0.99. The consensus estimate for Insulet's current full-year earnings is $3.17 per share. William Blair also issued estimates for Insulet's Q1 2025 earnings at $0.83 EPS, Q2 2025 earnings at $0.84 EPS and FY2025 earnings at $3.91 EPS.

A number of other research firms have also recently issued reports on PODD. Raymond James raised their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Barclays boosted their price target on shares of Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a research report on Monday. Morgan Stanley boosted their target price on shares of Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a report on Monday. Piper Sandler boosted their price target on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Finally, Canaccord Genuity Group boosted their price target on shares of Insulet from $236.00 to $269.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.27.

Insulet Price Performance

Insulet stock traded down $6.04 during mid-day trading on Wednesday, hitting $269.06. The stock had a trading volume of 407,782 shares, compared to its average volume of 780,076. The firm has a market capitalization of $18.87 billion, a P/E ratio of 46.54, a P/E/G ratio of 4.26 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm's 50 day moving average is $234.83 and its 200 day moving average is $206.03. Insulet has a one year low of $160.19 and a one year high of $279.40.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. boosted its stake in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 58 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 133 shares during the period. International Assets Investment Management LLC purchased a new stake in Insulet during the second quarter valued at about $32,000. UMB Bank n.a. raised its holdings in Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 81 shares during the period. Finally, CVA Family Office LLC boosted its holdings in shares of Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after acquiring an additional 145 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.